Back to School: How biopharma can reboot drug development. Access exclusive analysis here

PEG-Intron Phase II combination data

Schering-Plough (SGP) presented results of an open label Phase II dose-ranging study of PEG-Intron with its Rebetol ribavirin nucleoside analog in

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE